This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings

For the quarter ended June 2026, Journey Medical Corporation (DERM) reported revenue of $18.51 million, up 23.3% over the same period last year. EPS came in at -$0.01, compared to -$0.16 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $18.72 million, representing a surprise of -1.1%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.01.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Journey Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Total net product revenue- Accutane: $3.36 million versus $3.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.1% change.
Product revenue, net: $17.84 million versus the two-analyst average estimate of $18.03 million.
Total net product revenue- EmrosiTM: $8.07 million compared to the $7.39 million average estimate based on two analysts.
Total net product revenue- Qbrexza: $5.11 million versus the two-analyst average estimate of $6.83 million. The reported number represents a year-over-year change of -26.4%.

View all Key Company Metrics for Journey Medical here>>>

Shares of Journey Medical have returned -11.2% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Journey Medical Corporation (DERM): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research